Mirati Therapeutics said Monday that more than 60% of patients with lung cancer showed confirmed tumor responses when its experimental KRAS-blocking drug was added to Merck’s Keytruda immunotherapy.
While the study results are preliminary and derived from only eight patients, Mirati is hoping that a promising combination therapy in lung cancer will help narrow the competitive gap with its biggest rival, Amgen.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
